Rapid tests that are low-cost and portable are the first line of defence in healthcare systems. Dipstick and lateral-flow are the two universal assay formats as they are lightweight and compact, and provide qualitative results without external instrumentation. However, existing formats have limitations in the quantification of analyte concentrations. Hence, the demand for sample preparation, improved sensitivity and user-interface has challenged the commercial products. Recently, capabilities, sensors and readout devices were expanded to multiplexable assays platforms, which might transcend the capabilities of existing design format of diagnostic tests. This chapter outlines the evolution of diagnostic devices and current trends in the development of qualitative and quantitative sensing devices for applications in healthcare, veterinary medicine, environmental monitoring and food safety. The chapter also discusses design parameters for diagnostics, their functionalisation to increase the capabilities and the performance, emerging sensing platforms and readout technologies. The factors which limit the emerging rapid diagnostics to become commercial products are also discussed.The life expectancy has grown worldwide, which also increased the healthcare spending [1, 2]. For example, 720 million people will be aged 65 or older by 2020. Currently four in five people over the age of 75 take at least one prescribed medicine, and this trend is set to increase [3]. For some of the medications, large pharma find it the hard to recover R&D costs while the pressure from the regulatory agencies also increased for the use of new drugs as the first line of defence based on efficacy and cost. Hence, the global healthcare trends and ever increasing pressure from regulatory agencies put a strong case for the development of diagnostics for healthcare monitoring as well as the evaluation of drug efficacies in clinical trials. All these considerations parallels governments' and insurance companies' interests in obtaining the best performance possible and treatment benefits they support. These trends are behind the driving force for the development of diagnostics that can reduce the healthcare costs by developing effective drugs and identifying diseases and conditions at an early stage.The major stumbling block in monitoring and controlling diseases/contaminations remains delivering simple, low-cost and robust diagnostic tests [4,5]. In the developing world, the basic healthcare infrastructure and trained healthcare personnel are